

Europad

European Opiate Addiction Treatment Association



**7th European
Congress on**

Heroin Addiction &

Related Clinical Problems

European Opiate Addiction Treatment Association

**6-8 October
2006**

www.europad.org

Radisson SAS Hotel
BRATISLAVA
SLOVAK REPUBLIC

Final Program

Supported by

Bratislava Municipality

G. De Lisio Institute of Behavioural Sciences, Pisa, Italy
Italian Journal of Addictions
Heroin Addiction and Related Clinical Problems

Promoted by

European Opiate Addiction Treatment Association - EUROPAD
Slovak Professional Society for Dependencies on Psychoactive Substances
Italian Society of Addictions - SITD
From Science to Public Policy Association - AU CNS



Presidents	I. Maremmani (Pisa, Italy) L. Okruhlica (Bratislava, Slovak Republic)
Scientific Committee	
Coordinators	I. Maremmani (Pisa, Italy) L. Okruhlica (Bratislava, Slovak Republic) M. Reisinger (Brussels, Belgium) P.P. Pani (Cagliari, Italy)
Members	M. Arieli (Jerusalem, Israel) O. Blix (Jonkoping, Sweden) C. Brewer (London, United Kingdom) M. Casas (Barcelona, Spain) K. Chmielewska (Warszawa, Poland) J.J. Deglon (Geneve, Switzerland) S. Dvoryak (Kiev, Ukraine) M. Farrell (London, United Kingdom) G. Fischer (Vienna, Austria) A. Ivancic (Porec, Croatia) J.M. Guffens (S.Tropez, France) A. Kantchelov (Sofia, Bulgaria) A. Kastelic (Ljubljana, Slovenja) A. Kozlov (Moscow, Russia) M. Krausz (Hamburg, Germany) M. Lovrecic (Ljubljana, Slovenja) N. Mehic-Basara (Sarajevo, Bosnia and Herzegovina) H. Mell (Jerusalem, Israel) M. Pacini (Pisa, Italy) L. Patricio (Lisbon, Portugal) P. Quigley (Dublin, Ireland) W. Rudalski (Warszawa, Poland) R. Schmid (Vienna, Austria) E. Subata (Vilnius, Lithuania) A. Tagliamonte (Siena, Italy) K. Thau (Vienna, Austria) M. Torrens (Barcelona, Spain) D. Touzeau (Paris, France) P. Vossenbergh (Deventer, The Netherlands) N. Vuckovic (Novi Sad, Serbia and Crna Gora) H. Waal (Oslo, Norway)

Organizing Committee

Ti.Gi. Congress
Via Udine, 12
58100 GROSSETO, Italy, EU
Phone: +39 0564412038- Fax: +39 0564412485
E-mail: info@tigicongress.com

AU-CNS
via XX Settembre, 83
55045 PIETRASANTA, Italy, EU
Phone: +39 0584790073
Fax: +39 058472081
E-mail: aucns@libero.it

Friday, October 6th, 2006			
10:00	Roundtable - What Is the Best Treatment for Russian Opiate Addicts? Selected Papers		
12:30	Welcome Reception at Bratislava City Hall		
14:00	SP-CME Pre-conference Workshop - Buprenorphine Educational Meeting		
17:00	<i>Opening Ceremony</i> (I. Maremmani, Pisa, Italy, EU and L. Okruhlica, Bratislava, Slovak Republic, EU)		
17:30	Introduction - M. Parrino (New York, USA)		
18:00	Main Lecture - M. Farrell (London, U.K., EU)		
19:00	Main Lecture - R. Newman (New York, U.S.A.)		
20:00	<i>Welcome Cocktail and EUROPAD Chimera Award</i>		
Saturday, October 7th, 2004			
9:30	Main Lecture - M. Gossop (London, U.K., EU)		
10:30	<i>Coffee Break</i>		
11:00	Symposium 1 Heroin Addiction and Related Clinical Problems Chairman: G.Gerra (Rome, Italy)	Symposium 2 Psychosis, Depression and Opioid Agonist Treatment Chairman: J.J. Deglon (Geneve, Switzerland)	Symposium 3 New Approaches in the Treatment of Opioid Dependency During Pregnancy Chairman: K. Kaltenbach (Philadelphia, PL, USA)
13:30	<i>Lunch</i>		
14:30	Symposium 4 Heroin Addiction, Hepatitis, HIV/AIDS <i>(In Memory of J.M. Guffens)</i> Chairman: S. Walcher (Munich, Germany)	Symposium 5 Maintenance Treatment in Primary Health Care: Voices of Experience Chairman: A. Ivancic (Porec, Croatia)	Symposium 6 Buprenorphine Treatment: An Update Chairman: D. Touzeau (Paris, France)
17:00	<i>Coffee break</i>		
17:30	Symposium 7 Integration of Therapeutic and Psychosocial Services in Methadone Maintenance Treatment Chairman: A. Kantchelov (Sofia, Bulgaria)	Symposium 8 Methadone, Buprenorphine and Health Hazards? Chairman: H. Waal (Oslo, Norway)	Symposium 9 Methadone Pharmacokinetics Chairman: L. Okruhlica (Bratislava, Slovak Republic)
20:00	<i>End of Session</i>		
Sunday, October 8th 2006			
9:30	Main Lecture - W. Ling (Los Angeles, CA, USA)		
10:30	<i>Coffee Break</i>		
11:00	Symposium 10 Psychosocial Aspects of Heroin Addiction Chairman: P. Quigley (Dublin, Ireland)	Symposium 11 Substitution Treatment in Prisons Chairman: A. Kastelic (Ljubljana, Slovenija)	Symposium 12 Substitution Treatment in Eastern-Europe Chairman: S. Dvoryak (Kiev, Ukraine)
13:45	Closing Remarks - M. Reisinger (Brussels, Belgium)		

PROGRAM

9:00-10:00 Registration of Participants

Friday, October 6th, 2006: Room A

ROUNDTABLE

WHAT IS THE BEST TREATMENT FOR RUSSIAN OPIATE ADDICTS?

Chairman:

A. Kozlov and T. Klimenko (Moscow, Russian Federation)

- 10:00-10:30 **A. Polunina** (*Moscow, Russian Federation*)
Brain Disintegration in Opioid Addicts: Role of Natural Course of the Disease and Role of Methadone
- 10:30-11:00 **T. Klimenko and A. Kozlov** (*Moscow, Russian Federation*)
Heroin Dependence in the Russian Federation: the Current Situation
- 11:00-11:30 **L. Blagov** (*Moscow, Russian Federation*)
Peculiar Clinical Properties of Heroin Dependence in the Formation Stage of Young Females
- 11:30-12:00 **O. Kaverina** (*Astrakhan, Russian Federation*)
Medical Aspects Regarding International Combat Against Drug Aggression

Friday, October 6th, 2006: Room B

HEROIN ADDICTION AND RELATED CLINICAL PROBLEMS.

SELECTED PAPERS

Chairman:

L. Okruhlica (Bratislava, Slovak Republic)

- 9:00-9:30 **L. Steliar** (*Bratislava, Slovak Republic*)
Decrease in Drug Injecting Associated with Changes in the Drug Scene
- 9:30-10:00 **Z. Alexandercikova** (*Bratislava, Slovak Republic*)
Specificity of Clinical Opiate Withdrawal Scale: Opiate vs. Alcohol and Methamphetamine Dependence
- 10:00-10:30 **L. Okruhlica** (*Bratislava, Slovak Republic*)
Absence of Intrauterine Growth Retardation in Babies of Mothers Stabilized on Methadone Before Conception and During the Whole Pregnancy
- 10:30-11:00 **M. Stenbacka**, (*Stockholm, Sweden*)
A 37-Year Follow-up of Opiate Abuse. Analyses of Morbidity and Mortality
- 11:00-11:30 **G. Gerra** (*Rome, Italy*)
The K-antagonism: Clinical Implications
- 11:30-12:00 **M. Reisinger** (*Brussels, Belgium*)
Injecting Buprenorphine Tablets: a Manageable Risk

12:30-13:45 Welcome Reception at Bratislava City Hall

Friday, October 6th, 2006: Plenary Room

PRE-CONFERENCE WORKSHOP

BUPRENORPHINE EDUCATIONAL MEETING

Chairmen:

I. Maremmani (Pisa, Italy, EU) - L. Okruhlica (Bratislava, Slovak Republic, EU)

- 14:00-14:25 **S. Walsh** (*Baltimore, Maryland, USA*)
Pharmacology of Buprenorphine: The Combination Buprenorphine/Naloxone
- 14:25-14:50 **N. Lintzeris** (*Melbourne, Australia*)
Understanding Dose Titrations & Protocols: Best Practice
- 14:50-15:15 **E. McCance-Katz** (*Richmond, Virginia, USA*)
Drug Interactions with HIV Therapies
- 15:15-15:40 **S. Walcher** (*Munich, Germany, EU*)
Treating HIV/HCV
- 15:40-16:05 **T. Kosten** (*Houston, Texas, USA*)
Cocaine Abuse and Buprenorphine
- 16:05-16:30 **I. Maremmani** (*Pisa, Italy, EU*)
Treating Dual Diagnosis Heroin Addicts
- 16:30-16:55 **W. Ling** (*Los Angeles, California, USA*)
Pain Management

Sponsored by Schering-Plough.

Simultaneous translation in French and Slovak languages will be provided if the number of participants is consistent

Friday, October 6th, 2006: Plenary Room

OPENING LECTURES

Chairmen:

I. Maremmani (Pisa, Italy, EU) - M. Reisinger (Brussels, Belgium, EU)

- 17:00-17:30 **I. Maremmani** (*Pisa, Italy, EU*) & **L. Okruhlica** (*Bratislava, Slovak Republic, EU*)
Welcome Addresses and Opening Remarks
- 17:30-18:00 **M. Parrino** (*New York, New York, USA*)
The Necessity of a World Federation of Health Organizations Providing Opiate Agonist Therapy for Heroin Addicts
- 18:00-19:00 **M. Farrell** (*London, UK, EU*)
Restoring Quality of Life in Heroin Addicts
- 19:00-20:00 **R. Newman** (*New York, New York, USA*)
General Practitioners: Indispensable for Optimal Treatment of Opiate Addiction

20:30-22:30

WELCOME COCKTAIL AND EUROPAD CHIMERA AWARD 2006

Chairmen:

I. Maremmani (Pisa, Italy, EU) - M. Reisinger (Brussels, Belgium, EU)

To be Awarded: **Ante Ivancic** (*Porec, Croatia*),
Gilberto Gerra (*Roma, Italy, EU*), **M. Torrens** (*Barcelona, Spain, EU*)

Saturday, October 7th, 2006: Plenary Room

MAIN LECTURE

Chairman:

M. Reisinger (Brussels, Belgium, EU)

9:30-10:30 **M. Gossop** (*London, UK, EU*)
Methadone Treatment: Is It Enough?

10:30-11:00 Break

Saturday, October 7th, 2006: Plenary Room

SYMPOSIUM 1

HEROIN ADDICTION AND RELATED CLINICAL PROBLEMS

Chairman:

G. Gerra (Roma, Italy, EU)

- 11:00-11:30 **O. Espegren** (*Kristiansand, Norway*)
Stimulant Treatment of ADHD Patients in a Methadone Maintenance Programme. A Pilot Study
- 11:30-12:00 **K. R. Dyer** (*Crawley, Australia*)
The Use of Oral Fluid for Drug Screening and Therapeutic Drug Monitoring Among Methadone Maintenance Patients
- 12:00-12:30 **M. Astals** (*Barcelona, Spain, EU*)
Personality Traits in Opioid Addicts Who Are Non-responders to Methadone Maintenance Treatment
- 12:30-13:00 **F. Fonseca** (*Barcelona, Spain, EU*)
Prevalence of QT Interval Enlargement, Related Factors, and Clinical Implications in Methadone Maintenance Treated Patients
- 13:00-13:30 **S. Slezakova**, (*Bratislava, Slovak Republic, EU*)
Weight Gain in Methadone Maintenance as a Return to the Population Norm

Saturday, October 7th, 2006: Room 1

SYMPOSIUM 2

PSYCHOSIS, DEPRESSION AND OPIOID TREATMENT

Chairman:

J. J. Deglon (Geneve, Switzerland)

- 11:00-11:30 **N. Vuckovic** (*Novi Sad, Srbija*)
Relapse in Heroin Addiction and Depression
- 11:30-12:00 **A.S. Trajanovska** (*Skopje, R. Makedonija*)
Effectiveness of Sertraline in Treatment of Depressive Disorders in Methadone Maintenance Patients
- 12:00-12:30 **O. Subotin-Popovska** (*Skopje, R. Makedonija*)
Treatment of Opiate Abuse and Psychosis
- 12:30-13:30 **J.J. Deglon** (*Geneva, Switzerland*)
Methadone: a Remarkable Anti-anxiety, Antidepressant and Antipsychotic Agent

Saturday, October 7th, 2006: Room 2

SYMPOSIUM 3

NEW APPROACHES IN THE TREATMENT OF OPIOID DEPENDENCY DURING THE PREGNANCY

Chairman:

K. Kaltenbach (Philadelphia, Pennsylvania, USA)

- 11:00-11:30 **P. Selby** (*Toronto, Ontario, Canada*)
Management of Pain for Women Maintained on Buprenorphine and Methadone:
Intrapartum and Post Partum Strategies
- 11:30-12:00 **H. Jones** (*Baltimore, Maryland, USA*)
Transitioning from Opioids onto Buprenorphine During Pregnancy
- 12:00-12:30 **S. Heil** (*Burlington, Vermont, USA*)
The Use of Voucher-based Incentives to Reduce Drug Use During Pregnancy
- 12:30-13:00 **G. Fischer**, (*Vienna, Austria, EU*)
New Approaches for Treating Opioid Dependence During Pregnancy: A European
Perspective
- 13:00-13:30 **K. Kaltenbach** (*Philadelphia, Pennsylvania, USA*)
Neonatal Abstinence Syndrome: An Update on Assessment and Treatment

13:30-15:00 Break

Saturday, October 7th, 2006: Plenary Room

SYMPOSIUM 4

HEROIN ADDICTION, HEPATITES, HIV/AIDS

Chairman:

S. Walcher (Munich, Germany, EU)

- 14:30-15:00 **S. Walcher** (*Munich, Germany, EU*)
Infectious Diseases and Mortality in Heroin Addiction
- 15:00-15:30 **M. Lovrecic** (*Ljubljana, Slovenja, EU*)
Infectious Diseases and Mortality in Heroin Addiction
- 15:30-16:00 **M. Bary** (*Paris, France, EU*)
Observational Study: Contribution of the FibroScan® to Healthcare Access for Drug
Users and Precarious Population
- 16:00-16:30 **S. Holcikova** (*Bratislava, Slovak Republic, EU*)
Good Prognosis for Three Quarters of HCV Infected Drug Users in Bratislava
- 16:30-17:00 **M. Pacini** (*Pisa, Italy, EU*)
Medically Assisted Rehabilitation for Heroin Addicts and HIV Prevention

Saturday, October 7th, 2006: Room 1

SYMPOSIUM 5

MAINTENANCE TREATMENT IN PRIMARY HEALTH CARE

VOICES OF EXPERIENCE

Chairman:

A. Ivancic (Porec, Croatia)

- 14:30-15:00 **A. Coppel** (*Paris, France, EU*)
The French Outcomes in Maintenance Treatments. Historical Context and Present Public Debate
- 15:00-15:30 **C. Fahrmbacher – Lutz** (*Augsburg, Germany, EU*)
Augsburg-Presentation of the Network to Handle Problems with Maintenance Therapy
- 15:30-16:00 **C. Ford** (*London, UK, EU*)
Supporting GP's in Improved Prescribing for Opiate Users
- 16:00-16:30 **A. Ulmer** (*Stuttgart, Germany, EU*)
Maintenance – How Long ? Treatment of Alcohol Addicts Former Heroin Addicts. Experiences from a German Practice
- 16:30-17:00 **A. Ivancic** (*Porec, Croatia*)
Fifteen Years of Office Based Prescribing in Croatia – Attitudes, Obstacles and Outcomes

Saturday, October 7th, 2006: Room 2

SYMPOSIUM 6

BUPRENORPHINE TREATMENT: AN UPDATE

Chairman:

D. Touzeau (Paris, France, EU)

- 14:30-15:00 **L. Patricio** (*Lisbon, Portugal, EU*)
Six Years Evaluation of Treatment with Subutex: Follow Up of Heroin Addicts in a Comprehensive and Integrated Substitution (Taipas Centre, Lisbon)
- 15:00-15:30 **M. Heilig** (*Bethesda, Maryland, USA*)
A Stepped Care Strategy Utilizing Buprenorphine and Methadone vs. Conventional Methadone Maintenance in Heroin Dependence
- 15:30-16:00 **N. Lintzeris** (*Melbourne, Australia*)
Methadone and Buprenorphine with Benzodiazepines (Low and High Doses)
- 16:00-16:30 **B. Skjervold** (*Trondheim, Norway*)
Clinical Experience with Buprenorphine in Maintenance Treatment in Central Norway
- 16:30-17:00 **H. Alho** (*Helsinki, Finland, EU*)
Buprenorphine and Buprenorphine/Naloxone Experience in Finland

17:00-17:30 Break

Saturday, October 7th, 2006: Plenary Room

SYMPOSIUM 7

**INTEGRATION OF THERAPEUTIC AND PSYCHOSOCIAL SERVICES IN METHADONE
MAINTENANCE TREATMENT**

Chairman:

A. Kantchev (Sofia, Bulgaria)

- 11:00-11:30 **I. Marion** (*New York, New York, USA*)
Providing Comprehensive Treatment in Medication Assisted Opioid Treatment – A Needs-based Model
- 11:30-12:00 **R. Bes** (*Amsterdam, The Netherlands. EU*)
Motivational Interviewing: Linking Systems & Dancing with Clients
- 12:00-12:30 **H. Joseph** (*New York, New York, USA*)
From Harm Reduction to Methadone Treatment: A Continuum of Medical Care and Public Health Policy
- 12:30-13:00 **A. Kantchev** (*Sofia, Bulgaria*)
Methadone-Assisted Comprehensive Therapy: a Transtheoretical Model
- 13:00-13:30 **E. Curet** (*New York, New York, USA*)
Psychosocial Services at the Vincent P. Dole Research and Treatment Institute for Opiate Dependence

Saturday, October 7th, 2006: Room 1

SYMPOSIUM 8

METHADONE: EFFECTS AND SIDE EFFECTS

Chairman:

H. Waal (Norway)

- 17:30-18:00 **H. Waal** (*Oslo, Norway*)
Methadone. Not that Innocent After All - and Is Buprenorphine a Healthier Alternative?
- 18:00-18:30 **M.Z. Mintzer** (*Baltimore, Maryland, USA*)
Methadone, Buprenorphine and Cognitive Performance.
- 18:30-19:00 **M.J. Krantz** (*Denver, Colorado, USA*)
QTc Prolongation: A Problem in Opioid Maintenance? Facts and Fantasies
- 19:00-19:30 **R. Brown** (*Madison, Wisconsin, USA*)
Methadone and Buprenorphine Maintenance and Sexual Dysfunction
- 19:30-20:00 **K. Anchersen** (*Oslo, Norway*)
A Prospective Study of Wanted and Unwanted Effects of Replacement Therapy. Buprenorphine and Methadone in Comparison.

Saturday, October 7th, 2006: Room 2

SYMPOSIUM 9

METHADONE PHARMACOKINETICS

Chairman:

L. Okruhlica (Bratislava, Slovak Republic, EU)

- 17:30-18:00 **L. Okruhlica** (*Bratislava, Slovak Republic, EU*)
Methadone Dose, Methadone Serum Concentration, and BMI
- 18:00-18:30 **K. Wolff** (*London, UK, EU*)
The Influence of Body Mass Index on Plasma Methadone Concentration
- 18:30-19:00 **C. B. Eap** (*Prilly, Switzerland*)
Pharmacokinetics and Pharmacogenetics of Methadone
- 19:00-19:30 **M. Torrens** (*Barcelona, Spain, EU*)
Methadone Plasma Levels and QT
- 19:30-20:00 **P. P. Pani** (*Cagliary, Italy, EU*)
Variability in Methadone Response: Pharmacokinetics Issues

END OF SESSION

Sunday, October 8th, 2006: Plenary Room

MAIN LECTURE

Chairman:

P.P. Pani (Cagliari, Italy, EU)

9:30-10:30 **W. Ling** (*Los Angeles, California, USA*)
Buprenorphine Treatment: Hot Issues for Cool Heads

10:30-11:00 Break

Sunday, October 8th, 2006: Plenary Room

SYMPOSIUM 10

PSYCHOSOCIAL ASPECTS OF HEROIN ADDICTION

Chairman:

P. Quigley (Dublin, Ireland, EU)

17:30-18:00 **P. Quigley** (*Dublin, Ireland, EU*)
Psychosocial Influences on the Methadone Treatment Environment

18:00-18:30 **E. Subata** (*Vilnius, Lithuania, EU*)
Methadone Maintenance Treatment Impact on Quality of Life and Health of Opioid Dependent Persons in Lithuania

18:30-19:00 **M. Pacini** (*Pisa, Italy, EU*)
Medical Meaning of Psychosocial Issues of Heroin Addiction

19:00-19:30 **S. Bauer** (*Vienna, Austria, EU*)
Gender Differences and Mortality Predictors in Opioid Dependent Patients

19:30-20:00 **I. Brajeviæ-Gizdiæ** (*Split, Croatia*)
Sexual Behaviour of Heroin Addicts in Treatment

Sunday, October 8th, 2006: Room 1

SYMPOSIUM 11

SUBSTITUTION TREATMENT IN PRISONS

Chairman:

A. Kastelic (Ljubljana, Slovenia, EU)

11:00-11:30 **A. Kastelic** (*Ljubljana, Slovenia, EU*)
Substitution Treatment in Prisons

11:30-12:00 **M. Pacini** (*Pisa, Italy, EU*)
Clinical Foundation for the Use of Methadone in Jail

12:00-12:30 **F. Lamanna** (*Pisa, Italy, EU*)
Methadone and Buprenorphine in Criminal Addicts

12:30-13:00 **M. Parrino** (*New York, New York, USA*)
Methadone and Buprenorphine Treatment Throughout the Criminal Justice System

13:00-13:30 **H. Stover** (*Bremen, Germany, EU*)
Substitution Treatment in Prison

Sunday, October 8th, 2006: Room 2

SYMPOSIUM 12
SUBSTITUTION TREATMENT IN EASTERN-EUROPE

Chairman:
S. Dvoryak (Kiev, Ukraine)

- 11:00-11:30 **S. Dvoryak** (*Kiev, Ukraine*)
Ukrainian Context of ST. A Long Way of Non-Implementation. Political Difficulties vs Clinical Success
- 11:30-12:00 **E. Subata** (*Vilnius, Lithuania*)
Political and Social Aspects of ST Implementation in Lithuania
- 12:00-12:30 **B. Habrat** (*Warsaw, Poland*)
15-Year Battle for Introducing and Developing ST in Poland
- 12:30-13:00 **A. Kantchelov** (*Sofia, Bulgaria*)
From Harm Reduction to Methadone Assisted Therapy. 10 Year of Bulgarian Experience

13:30-13:45 Break

Sunday, October 8th, 2006: Plenary Room

13:45-14:00 **M. Reisinger** (*Brussels, Belgium, EU*)
Closing remarks

Faculty

H. Alho	Unit on Prevention and Treatment of Addictions, Department of Mental Health and Alcohol Research, National Public Health Institute (KTL), Helsinki, Finland, EU
Z. Alexandercikova	Centre for Treatment of Drug Dependencies, Bratislava, Slovak Republic, EU
K. Anchersen	Unit for Addiction Medicine, University of Oslo, Oslo, Norway
M. Astals	IAPS, Hospital del Mar, Barcelona, SPAIN, EU
M. Bary	Centre du Moulin Joly, French Red Cross, Paris, France, EU
S. Bauer	Department of Psychiatry, Medical University of Vienna, Austria, EU
R. Bes	Amsterdam Centre for Motivation and Change, Amsterdam, The Netherlands, EU
L. Blagov	Russian State Medical University, Moscow, Russian Federation
I. Brajeviæ-Gizdiæ	Public Health Institute of Split and Dalmatian County, Department for Prevention of Addiction, Split, Croatia
R. Brown	University of Wisconsin, Department of Family Medicine, Madison, Wisconsin, USA
A. Coppel	Association Francaise de Reduction des Risques (AFR), Paris, France, EU
E. Curet	The Vincent P. Dole Research and Treatment Institute for Opiate Disorders, The Weill Cornell Medical College, Department of Public Health. New York, N.Y., USA
J. J. Deglon	Fondation Phoenix, Geneve, Switzerland
S. Dvoryak	Ukrainian Institute on Public Health Policy, Kiev, Ukraine
K. R. Dyer	School of Medicine & Pharmacology, University of Western Australia, Crawley, Australia
C. B. Eap	DUPA, Hospital de Cery, Prilly-Lausanne, Switzerland
O. Espegren	Sorlandet Sykehus HF, Kristiansand, Norway
C. Fahrmbacher – Lutz	Die Ludwigs Apotheke, Augsburg, Germany, EU
M. Farrell	National Addiction Centre, Institute of Psychiatry, London, UK, EU
G. Fischer	Addiction Clinic, Department of Psychiatry, Medical University of Vienna, Austria, EU
F. Fonseca	IAP-SMT, Hospital del Mar, Barcelona, Spain, EU
C. Ford	Lonsdale Medival Centre, London, UK, EU
G. Gerra	DNPA, Rome, Italy, EU
M. Gossop	King's College, University of London, UK, EU
B. Habrat	Institute of Psychiatry and Neurology, Warsaw, Poland, EU
S. Heil	University of Vermont, Burlington, Vermont, USA
M. Heilig	NIAAA, Bethesda, Maryland, USA
S. Holcikova	Centre for Treatment of Drug Dependencies, Bratislava, Slovak Republic, EU

A. Ivancic	Center for Addiction Treatment, Porec, Croatia
H. Jones	Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
H. Joseph	NAMA, New York, N.Y., USA
K. Kaltenbach	Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
A. Kantchelov	Kantchelov Clinic, Sofia, Bulgaria
A. Kastelic	SEEA network, Ljubljana, Slovenija, EU
O. Kaverina	Regional Department of Intersectoral Coordination in Astrakhan, Russian Federation State Service of Narcotrafic Control, Astrakhan, Russian Federation
T. Klimenko	Department of Narcology, “V.P. Serbsky” State Scientific Center for Social and Forensic Psychiatry, Moscow, Russian Federation
T. Kosten	Division of Alcohol and Addictive Disorders, Baylor College of Medicine, Houston, Texas, USA
A. Kozlov	Medical Department of Russian Federation State Service of Narcotrafic Control, Moscow, Russian Federation
M. J. Krantz	Colorado Prevention Center, Denver, Colorado, USA
F. Lamanna	SerT Pisa, Italy, EU
W. Ling	Dept. Psychiatry & Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, California, USA
N. Lintzeris	The Western Hospital, Turning Point, Melbourne, Australia
M. Lovrecic	National Institute of Health, Ljubljana, Slovenija
I. Maremmani	Vincent P. Dole Research Team, Santa Chiara University Hospital, Department of Psychiatry, University of Pisa, Italy
I. Marion	Division of Substance Abuse, Albert Einstein College of Medicine, Bronx, New York, USA
E. McCance-Katz	Virginia Commonwealth University, USA
M. Z. Mintzer	Department of Psychiatry and Behavioral Sciences, Behavioral Biology Research Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
R. Newman	The Baron Edmond de Rothschild Chemical Dependency Institute, Continuum Health Partners, Inc., Beth Israel Medical Center, New York, New York, USA
L. Okruhlica	Centre for Treatment of Drug Dependencies - Institute on Drug Dependencies, Bratislava, Slovak Republic
M. Pacini	“G. De Lisio” Institute of Behavioural Sciences. Pisa, Italy
P. P. Pani	SerT AUSL 8, Cagliari, Italy, EU.
M. Parrino	AATOD, New York, N.Y., USA
L. Patricio	Taipas Centre - Lisbon, Portugal
A. Polunina	Moscow Scientific Practical Center of Narcology, Moscow, Russian Federation

P. Quigley	Dept of Epidemiology and Public Health Medicine, Queens University Belfast, Northern Ireland, EU
M. Reisinger	EUROPAD, Bruxelles, Belgium, EU
P. Selby	Centre for Addiction and Mental Health, Toronto, Ontario, Canada
B. Skjervold	LAR-Midt, Trondheim, Norway
S. Slezáková	Centre for Treatment of Drug Dependencies, Bratislava, Slovak Republic, EU
I. Steliar	Institute on Drug Dependencies of the Centre for Treatment of Drug Dependencies Bratislava, Slovak Republic, EU
M. Stenbacka	Karolinska University Hospital, Stockolm, Sweden, EU
H. Stover	Faculty of Law, University of Bremen, Germany, EU
E. Subata	Vilnius University, Department of Psychiatry, Vilnius, Lithuania, EU
O. Subotin-Popovska	Skopje Psychiatric Hospital - Skopje, Republic of Makedonija
M. Torrens	Psychiatry Research Unit, Hospital del Mar, Barcelona, Spain, EU
D. Touzeau	Departement Addictions, Clinique Liberté, Bagneux, France, EU
A. S. Trajanovska	Skopje Psychiatric Hospital - Skopje, Republic of Makedonija
A. Ulmer	General Practitioner, Stuttgart, Germany, EU
N. Vuckovic	Clinical for Drug Addiction Institute for Psychiatry, Novi Sad, Serbja
H. Waal	Unit for Addiction Medicine, Institute of Psychiatry, University of Oslo. Norway
S. Walcher	CONCEPT, Centre for Addiction Medicine, Munich, Germany, EU
S. Walsh	John Hopkins University, Baltimore, Maryland, USA
K. Wolff	National Addiction Unit, London, UK, EU

Thanks to



Schering-Plough

for the welcome contributions to the Conference costs